The paper's citation list
No. | The paper's citation list |
|---|
1 | Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors. 2025;16: doi: 10.3389/fimmu.2025.1546717 |
2 | Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer. 2024;67:21520 doi: 10.1021/acs.jmedchem.4c02421 |
3 | Targeting KRAS: Crossroads of Signaling and Immune Inhibition. 2022;5:68 doi: 10.36401/JIPO-22-5 |
4 | Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. 2022;12: doi: 10.3389/fonc.2022.859455 |
5 | Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. 2021;12: doi: 10.3389/fimmu.2021.719116 |
6 | The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses. 2025;16: doi: 10.3389/fimmu.2025.1522699 |
7 | Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab. 2024;29:612 doi: 10.1007/s10147-024-02482-7 |
8 | Clone Wars: Quantitatively Understanding Cancer Drug Resistance. 2020;938 doi: 10.1200/CCI.20.00089 |
9 | Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence. 2023; doi: 10.7759/cureus.40031 |
10 | Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma. 2024;14: doi: 10.1038/s41598-024-74636-6 |
11 | Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota. 2023;13: doi: 10.3389/fonc.2023.1038710 |
12 | Resistance mechanisms to immune checkpoint inhibitors: updated insights. 2025;24: doi: 10.1186/s12943-024-02212-7 |
13 | The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. 2021;11: doi: 10.3389/fonc.2021.641428 |
14 | Breast Cancer Research and Treatment. 2023;188:29 doi: 10.1007/978-3-031-33602-7_2 |
15 | The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review. 2022;5:13 doi: 10.36401/JIPO-21-10 |
